sorafenib has been researched along with Ascites in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Attia, AA; El-Magd, MA; El-Naggar, SA; Eldiasty, JG; Elmetwalli, A; Mosallam, SAE; Nasser, HM; Salama, AF | 1 |
| Azzaroli, F; Benevento, F; Cabibbo, G; Caturelli, E; Cucchetti, A; Di Marco, M; Farinati, F; Foschi, FG; Gasbarrini, A; Giannini, EG; Guarino, M; Marra, F; Masotto, A; Mega, A; Missale, G; Morisco, F; Nardone, G; Oliveri, F; Pontillo, G; Raimondo, G; Rapaccini, GL; Rodolfo, S; Svegliati-Baroni, G; Trevisani, F; Vidili, G; Zoli, M | 1 |
| Bae, SH; Cheong, JY; Han, SY; Hwang, J; Kim, BH; Kim, DY; Kim, HY; Kim, YJ; Kwon, OS; Lee, HC; Lee, YJ; Paik, SW; Park, JW; Yeon, JE | 1 |
| Adeli, S; Ashabi, G; Nabavizadeh, F; Panahi, M; Samandari, H; Shafie Ardestani, M; Shafie, F | 1 |
| Joo, J; Kim, CM; Kim, H; Kim, HY; Lee, WJ; Park, JW; Woo, SM | 1 |
| Hsieh, YC; Huang, YT; Lee, FY; Lee, KC; Lee, PC; Lee, WP; Lin, HC; Liu, RS; Tan, TW; Yang, YY; Yeh, YC | 1 |
| Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM | 1 |
| Bitzer, M; Blondin, D; Dollinger, M; Erhardt, A; Gog, C; Häussinger, D; Kolligs, F; Lammert, F; Ohmann, C; Schott, E; Schuchmann, M; Walter, C; Wege, H | 1 |
3 trial(s) available for sorafenib and Ascites
| Article | Year |
|---|---|
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperbilirubinemia; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Sorafenib; Thrombocytopenia | 2019 |
Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib.
Topics: Ascites; Astrocytoma; Brain Neoplasms; Child; Humans; Magnetic Resonance Imaging; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Sorafenib; Ventriculoperitoneal Shunt | 2014 |
TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Ethiodized Oil; Fatigue; Hepatic Encephalopathy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
5 other study(ies) available for sorafenib and Ascites
| Article | Year |
|---|---|
Amygdalin potentiates the anti-cancer effect of Sorafenib on Ehrlich ascites carcinoma and ameliorates the associated liver damage.
Topics: Amygdalin; Animals; Antioxidants; Ascites; Carcinoma, Ehrlich Tumor; Liver; Matrix Metalloproteinase 9; Mice; Neoplasms; NF-E2-Related Factor 2; Sorafenib; Superoxide Dismutase; Vascular Endothelial Growth Factor A | 2022 |
Pattern of macrovascular invasion in hepatocellular carcinoma.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; End Stage Liver Disease; Female; Hepatectomy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Italy; Liver Diseases, Alcoholic; Liver Neoplasms; Liver Transplantation; Male; Mesenteric Veins; Middle Aged; Neoplasm Invasiveness; Non-alcoholic Fatty Liver Disease; Patient Acuity; Portal Vein; Prognosis; Registries; Sorafenib; Survival Rate; Tumor Burden | 2021 |
Sorafenib-loaded PAMAM dendrimer attenuates liver fibrosis and its complications in bile-duct-ligated rats.
Topics: Animals; Ascites; Bile Ducts; Collagen; Dendrimers; Dose-Response Relationship, Drug; Drug Carriers; Drug Liberation; Ligation; Liver; Liver Cirrhosis; Male; Rats; Rats, Wistar; Regional Blood Flow; Sorafenib; Vascular Endothelial Growth Factor A | 2019 |
Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Time Factors; Young Adult | 2013 |
Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.
Topics: Alanine; Animals; Ascites; Cytokines; DNA Primers; Fatty Liver; Fibroblast Growth Factors; Microcirculation; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Platelet-Derived Growth Factor; Positron-Emission Tomography; Rats; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Splanchnic Circulation; Triazines; Vascular Endothelial Growth Factor A | 2014 |